Correction Previously Distributed Press Release SciBase Holding AB (publ): Year-end Report 2018

Correction Previously Distributed Press Release SciBase Holding AB (publ): Year-end Report 2018

PR Newswire

STOCKHOLM, Feb. 20, 2019

STOCKHOLM, Feb. 20, 2019 /PRNewswire/ --

January 1December 31, 2018

The fourth quarter in figures

The full year in figures

Important events during the quarter

Important events after the end of the period


 

Oct 1 - Dec 31

Jan 1 - Dec 31

 

THE GROUP

 

2018

 

2017

 

2018

 

 

2017

 

Net sales, SEK ths

 

2 030

 

1 886

 

6 899

 

 

6 859

 

Gross margin, %

 

52,1%

 

31,5%

 

52,0%

 

 

35,4%

 

Equity/Asset ratio, %

 

88,1%

 

90,5%

 

88,1%

 

 

90,5%

 

Net indebtness, multiple

 

0,13

 

0,11

 

0,13

 

 

0,11

 

Cash equivalents, SEK ths

 

67 514

 

110 015

 

67 514

 

 

110 015

 

Cashflow from operating activities, SEK ths

 

-9 990

 

-11 358

 

-37 482

 

 

-44 180

 

Earnings per share (before and after dilution), SEK

 

-0,69

 

-1,13

 

-2,66

 

 

-5,00

 

Shareholder's equity per share, SEK

 

4,30

 

12,69

 

4,30

 

 

13,63

 

Average number of shares, 000'

 

16 618

 

9 118

 

16 618

 

 

8 493

 

Number of shares at closing of period, 000'

 

16 618

 

16 618

 

16 618

 

 

16 618

 

Share price at end of period, SEK

 

3,10

 

7,80

 

3,10

 

 

7,80

 

Number of sold electrodes, pieces

 

3 872

 

3 936

 

15 478

 

 

16 704

 

Average number of employees

 

19

 

20

 

19

 

 

21

This interim report has not been subject to review by the Company's auditors.This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 12.15 CET on February 20, 2019.

Contact person: Michael Colérus, CFO. +46 70 341 34 72

For more information, please contact: 
Simon Grant, CEO SciBase 
Phone: +46 72 887 43 99 
Email: simon.grant@scibase.com

Certified Advisor: 
Avanza AB 
Phone: +46 8 409 421 20 
Email: corp@avanza.se

About SciBase and Nevisense

SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed a unique point-of-care device for the accurate detection of malignant melanoma. Its first product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and a FDA clearance in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies and abnormalities. SciBase is listed on Nasdaq First North ("SCIB"). Further information is available at www.scibase.com

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/scibase/r/correction-previously-distributed-press-release-scibase-holding-ab--publ--year-end-report-2018,c2745553

The following files are available for download:

https://mb.cision.com/Main/12371/2745553/994652.pdf

PDF

 

Voltar noticias em Inglês